Saltar al contenido
Fuerza y músculoRevisión de evidencia3 min read

Depression is common in people with sarcopenia and linked to it, with wide variation between studies

Colectivo editorial MoveVitals · Study published · Reading updated

Original paper:Prevalence of depression in patients with sarcopenia and correlation between the two diseases: systematic review and meta-analysis. · Journal of cachexia, sarcopenia and muscle · 2022 · Artículo original ↗

Idea principal

Pooling 19 articles, the prevalence of depression among people with sarcopenia was 0.28 (95% CI 0.21 to 0.36), and sarcopenia was associated with depression (adjusted OR 1.57, 95% CI 1.32 to 1.86). Heterogeneity was large (I² 92.2% for prevalence), so the 0.28 figure is an average across very different studies.

Study design

Revisión de evidencia

Reading basis

Published abstract

Reading focus

Design & applicability

Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.

Pregunta de investigación

Depression is a leading cause of distress in later life, and sarcopenia (progressive loss of muscle mass, strength and function) often goes along with it. The authors asked how common depression is among people with sarcopenia and whether sarcopenia is independently associated with depression.

Población y método

Systematic review and meta-analysis. PubMed, Embase and Google Scholar were searched for papers on sarcopenia published up to 31 August 2021. The authors extracted the number of people with sarcopenia, the number with both sarcopenia and depression, and the odds ratio (OR) of sarcopenia for depression. Analyses used Meta-DiSc 1.4 software and Stata version 12.0.

Resultados

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    19 articles were included: 9 reported both prevalence and ORs, 4 reported prevalence only and 6 reported ORs only.
  2. 2
    For prevalence, the studies covered 1476 cases of sarcopenia and 364 of depression (mean age 75.5 years). The pooled prevalence of depression was 0.28 (95% CI 0.21 to 0.36), with significant heterogeneity (P < 0.001, I² = 92.2%).
  3. 3
    For the association, 16,869 subjects (mean age 73 years) gave an overall adjusted OR between sarcopenia and depression of 1.57 (95% CI 1.32 to 1.86), again with significant heterogeneity (P < 0.001, I² = 75.1%).

Límites e incertidumbre

  1. 1
    Heterogeneity was very high for prevalence (I² 92.2%) and substantial for the odds ratios (I² 75.1%), so a single pooled number hides large differences between studies.
  2. 2
    Most of the data are on older adults (mean ages 75.5 and 73 years), and the abstract does not say how sarcopenia or depression was defined in each study; definitions can differ.
  3. 3
    The abstract does not say whether the studies were cross-sectional or followed people over time, so the association cannot be read as showing which condition comes first. This reading is based on the abstract only.

Relevancia práctica

Low mood is common enough among older people with sarcopenia that it is worth mentioning, along with weakness, to a clinician. The association does not show that muscle loss causes depression or the reverse, and depression is treatable. Anyone with persistent low mood should seek professional help.

Tus datos

Grip strength, gait speed, activity level and sleep are measurable at home or on a wearable, and changes can come with mood changes. Use the same device and routine to watch your trend over weeks; a drop in activity or sleep quality together with low mood is a reason to talk to a clinician, not something a tracker can diagnose.

Cómo interpretar la evidencia

Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.

Resumen estructurado de los autores English

El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.

Background

Depression may be the most common cause of emotional distress later in life and can significantly reduce the quality of life in elderly individuals. Sarcopenia is a syndrome characterized by the continuous loss of skeletal muscle mass and decreased strength and function. In recent years, many studies have shown a correlation between sarcopenia and depression. The present study aimed to investigate the prevalence of depression among individuals with sarcopenia and to ascertain whether sarcopenia is independently associated with depression.

Methods

We systematically searched the PubMed, Embase, and Google Scholar databases for papers on sarcopenia published up to 31 August 2021. We reviewed the literature on the number of individuals with sarcopenia, the number of individuals with both sarcopenia and depression, and the odds ratio (OR) of sarcopenia to depression. Statistical analyses were performed using Meta-DiSc 1.4 software and Stata version 12.0.

Results

Nineteen articles met the inclusion criteria for review: nine reported both prevalence and ORs, four described prevalence only, and six detailed the ORs only. Regarding prevalence, there were 1476 cases of sarcopenia and 364 of depression in the selected studies; the mean age of the patients was 75.5 years, and the overall prevalence of depression was 0.28 [95% confidence interval (CI): 0.21-0.36]. Significant heterogeneity was noted (P < 0.001; I^(2) = 92.2%). In the case of ORs, there were 16 869 subjects with a mean age of 73 years; the overall adjusted OR between sarcopenia and depression was 1.57 (95% CI: 1.32-1.86). Significant heterogeneity was noted in the adjusted ORs (P < 0.001; I^(2) = 75.1%).

Conclusions

The prevalence of depression in patients with sarcopenia was high relatively, and there was a correlation between sarcopenia and depression.

Fuentes y atribución

Prevalence of depression in patients with sarcopenia and correlation between the two diseases: systematic review and meta-analysis.

Li Z, Tong X, Ma Y, Bao T, Yue J.

Journal of cachexia, sarcopenia and muscle · 2022-01-08

DOI: 10.1002/jcsm.12908 ↗PubMed · 34997702 ↗Europe PMC · Licencia registrada: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada

Fuentes verificadas 2026-11-01

Guías prácticas

Leer en contexto

·Revisión de revisiones

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Metaanálisis observacional

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
Fuerza y músculo →